ID: ALA5207476

Max Phase: Preclinical

Molecular Formula: C99H123ClFN11O27

Molecular Weight: 1953.57

Representations

Canonical SMILES:  CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](OC(=O)CCCc4cn(CCCNC(=O)[C@@H](Cc5ccccc5)NC(=O)[C@@H](Cc5ccccc5)NC(=O)CCC(=O)NCCCCCC(=O)N(CCCC[C@H](NC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)Cc5ccc(Cl)c(F)c5)nn4)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C

Standard InChI:  InChI=1S/C99H123ClFN11O27/c1-58-72(54-99(133)86(137-91(129)64-34-20-12-21-35-64)84-97(8,85(122)82(121)80(58)96(99,6)7)73(114)53-74-98(84,57-134-74)138-59(2)113)135-92(130)83(81(63-32-18-11-19-33-63)108-94(132)139-95(3,4)5)136-79(120)39-26-36-65-56-112(110-109-65)49-27-47-103-87(123)70(51-60-28-14-9-15-29-60)105-88(124)71(52-61-30-16-10-17-31-61)104-76(116)44-43-75(115)102-46-24-13-22-38-77(117)111(55-62-40-41-66(100)67(101)50-62)48-25-23-37-68(89(125)126)106-93(131)107-69(90(127)128)42-45-78(118)119/h9-12,14-21,28-35,40-41,50,56,68-74,81-84,86,114,121,133H,13,22-27,36-39,42-49,51-55,57H2,1-8H3,(H,102,115)(H,103,123)(H,104,116)(H,105,124)(H,108,132)(H,118,119)(H,125,126)(H,127,128)(H2,106,107,131)/t68-,69-,70+,71+,72-,73-,74+,81-,82+,83+,84-,86-,97+,98-,99+/m0/s1

Standard InChI Key:  VLNABXBROKSLEY-KDTLCVFESA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 1953.57

Molecular Weight (Monoisotopic): 1951.8262

AlogP:

#Rotatable Bonds:

Polar Surface Area:

Molecular Species:

HBA:

HBD:

#RO5 Violations:

HBA (Lipinski):

HBD (Lipinski):

#RO5 Violations (Lipinski):

CX Acidic pKa:

CX Basic pKa:

CX LogP:

CX LogD:

Aromatic Rings:

Heavy Atoms:

QED Weighted:

Np Likeness Score:

References

1. Machulkin AE, Uspenskaya AA, Zyk NY, Nimenko EA, Ber AP, Petrov SA, Shafikov RR, Skvortsov DA, Smirnova GB, Borisova YA, Pokrovsky VS, Kolmogorov VS, Vaneev AN, Ivanenkov YA, Khudyakov AD, Kovalev SV, Erofeev AS, Gorelkin PV, Beloglazkina EK, Zyk NV, Khazanova ES, Majouga AG..  (2022)  PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.,  227  [PMID:34717125] [10.1016/j.ejmech.2021.113936]

Source

Source(1):

• Scientific Literature